DrugCard stands out as an AI-enabled solution tailored for local literature screening within the pharmaceutical sector. Engineered to streamline drug safety procedures and ensure compliance with regulatory standards, DrugCard offers continuous and thorough screening, enabling pharmaceutical companies to remain abreast of the latest developments in their local markets.
With a focus on traceability and transparency, DrugCard empowers users to monitor the screening process meticulously, guaranteeing accuracy, completeness, and holistic coverage. The platform’s scalability to new markets makes it an ideal choice for companies aiming to expand their global footprint. Supporting multiple languages and suppliers, DrugCard facilitates a comprehensive screening process, fostering efficiency and reliability.
A notable advantage of DrugCard lies in its cost-effectiveness, requiring minimal capital investments. Despite its affordability, the platform maintains a high level of accuracy in scanned PDF screening, supporting over 100 languages and encompassing medical journals from over 35 countries.
Catering to various stakeholders within the pharmaceutical industry, including Contract Research Organizations (CROs), Marketing Authorization Holders (MAHs), and freelancers, DrugCard offers tailored benefits to each user group. CROs can enhance project management and screening outcomes, while MAHs can mitigate compliance and reputation risks through in-house screening. Freelancers benefit from time savings on literature screening, enabling them to focus on value-adding activities.
In summary, DrugCard emerges as a reliable and efficient solution for local literature screening, equipping the pharmaceutical industry with the essential tools to streamline drug safety processes and meet regulatory requirements effectively.
